Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,872 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07235319RecruitingPhase 3
Immediate vs delayed radiation after chemo-immunotherapy for metastatic NPC
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06936488Enrolling by invitation
Study of Ivonescimab with TAS-102 for advanced colorectal cancer
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
Huai'an, JiangsuAges 18–75 - NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT05727787Recruiting
Radiation trial for liver cancer that cannot be removed
This Phase I study tests a specific radiation approach (vGRID SBRT) for hepatocellular carcinoma (and some mixed types) that is advanced and cannot be cured with surgery or transplant. It aims to control tumors while staying within safety limits for the liver and nearby organs.
Kansas City, KansasAges 18 years+ - NCT05779423RecruitingPhase 2
Freezing tumor plus two immunotherapies for advanced melanoma
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
Boston, MassachusettsAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT07459309Recruiting
Combination treatment for liver cancer for people who can't have surgery
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07235566RecruitingPhase 2
MRG003 plus pucotenlimab for advanced thyroid cancer (ATC/PDTC)
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07383857Recruiting
PULSAR radiation plus immunotherapy for advanced abdominal or pelvic tumors
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07445412Recruiting
Liver regeneration study for patients with small future liver remnant
This trial tests techniques to help the liver grow before surgery in people who have a liver tumor and whose future liver remnant is too small. The goal is to make the liver big enough to safely remove the tumor.
Bologna, BolognaAges 18 years+ - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT03977571Recruiting
Surgery plus cancer drugs for kidney cancer that spread
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Aarhus, Central Region of DenmarkAges 18 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT06865547Enrolling by invitation
Managing metastatic hormone-sensitive prostate cancer with apalutamide
This trial tests a proactive management approach for men with metastatic hormone-sensitive prostate cancer who are starting apalutamide. It aims to see if this model helps improve how well the treatment works and how patients feel.
Guangzhou, GuangdongAges 18 years+ - NCT04919382RecruitingPhase 2
Temozolomide plus atezolizumab for advanced small cell lung cancer
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
Chicago, IllinoisAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+ - NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT04019678Recruiting
Breast cancer study after chemotherapy with small underarm node spread
This study looks at whether it’s safe and effective to avoid removing many underarm lymph nodes in some people who, after chemotherapy, still seem to have only tiny (“micro”) cancer deposits in the sentinel lymph node. It may help reduce treatment side effects while keeping cancer control.
Rozzano, MIAges 18–75 - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT06589804RecruitingPhase 3
Testing cetuximab plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
Little Rock, ArkansasAges 18 years+
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,872 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.